(MedPage Today) — Thirty warning letters were issued to telehealth companies for false and misleading claims about compounded GLP-1 receptor agonist products, the FDA announced on Tuesday.
The letters primarily targeted claims implying “sameness…
Source link : https://www.medpagetoday.com/publichealthpolicy/fdageneral/120144
Author :
Publish date : 2026-03-03 20:05:00
Copyright for syndicated content belongs to the linked Source.
